| CDXC on NASDAQ | Today's Change | Volume | 52 Week Range (Low/Hi) | Market Cap |
| 9.87US | 3.03% | 1,156,602 | 2.50 - 23.66 | 653.62M |
Contact Information
ChromaDex Corp.
Headquarters:10900 Wilshire Blvd., Suite 600
Los Angeles, California
USA, 90024
Tel: 310-388-6706
Fax: 949-419-0294
Email: Send a message
Website: Visit website
For more information...
Lead: Daniel GordonChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Rob Fried -Chief Executive Officer
Frank L. Jaksch, Jr. - Co-founder, Executive Chairman of the Board
Kevin Farr - Chief Financial Officer
Mark Friedman - General Counsel and Corporate Secretary
Ben Shichman - Chief Technical Officer
Aron Erickson - Vice President of R&D
Andrew Shao, Ph.D. - Senior Vice President, Global Regulatory & Scientific Affairs
Lisa Hatton Harrington - General Counsel & Corporate Secretary
Frank Fazio - Senior Vice President of Global Business
Rob Fried - Chief Executive Officer
Frank L. Jaksch Jr. - Co-founder, Executive Chairman of the Board
Stephen A. Block - Non-Executive Director
Jeffery Baxter - Non-Executive Director
Kurt Gustafson - Non-Executive Director
Steven D. Rubin - Non-Executive Director
Tony Lau - Non-Executive Director
Wendy Yu - Non-Executive Director
Stock Information
Press Releases
Company Overview
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Management
Rob Fried -Chief Executive Officer
Frank L. Jaksch, Jr. - Co-founder, Executive Chairman of the Board
Kevin Farr - Chief Financial Officer
Mark Friedman - General Counsel and Corporate Secretary
Ben Shichman - Chief Technical Officer
Aron Erickson - Vice President of R&D
Andrew Shao, Ph.D. - Senior Vice President, Global Regulatory & Scientific Affairs
Lisa Hatton Harrington - General Counsel & Corporate Secretary
Frank Fazio - Senior Vice President of Global Business
Board of Directors
Rob Fried - Chief Executive Officer
Frank L. Jaksch Jr. - Co-founder, Executive Chairman of the Board
Stephen A. Block - Non-Executive Director
Jeffery Baxter - Non-Executive Director
Kurt Gustafson - Non-Executive Director
Steven D. Rubin - Non-Executive Director
Tony Lau - Non-Executive Director
Wendy Yu - Non-Executive Director
Contact Information
10900 Wilshire Blvd., Suite 600
Los Angeles, California
90024, USA
Telephone: 310-388-6706
Fax: 949-419-0294
Email: Send a message
Website: Visit website